REN
ENSG00000143839
Target class
Enzyme
Chromosome
1
Approved drugs
1
Clinical candidates (approved and in development)
4
- Approved drugs
- 1
- ClinGen gene-disease validity
- Definitive
- Clinical candidates (approved and in development)
- 4
- Chemical probe available
- Yes
- Target name
- REN
- Gene name
- Renin
- Gene symbol
- REN
- Protein name
- Renin (EC 3.4.23.15) (Angiotensinogenase)
- Gene biotype
- Protein coding
- Gene family
- Peptidase family A1
- Target class
- Enzyme
- Target type
- Human gene
- Tissues expressed in
- 7
- Highest tissue expression
- 48.2
- Tissue specificity (Gini)
- 0.906
- Tissue specificity (tau)
- 0.986
- KEGG gene identifiers
- hsa:5972
- Reactome pathways
- R-HSA-2022377
- Protein interaction confidence
- 0.811442
- Protein interaction partners
- 52
- End position
- 204190324
- Start position
- 204154815
- Chromosome
- 1
- Strand
- Reverse
- Secreted . Membrane . Note=Associated to membranes via binding to ATP6AP2. .
Publication evidence
- PubMed 12045255
- Tissue specificity (tau)
- 0.986464
- Expression inequality (Gini)
- 0.906414
Expression in transcripts per million
- Kidney - Cortex
- 48.2
- Ovary
- 13.16
- Kidney - Medulla
- 7.6
- Uterus
- 2.72
- Fallopian Tube
- 1.8
Expression in transcripts per million
- Kidney - Cortex48.2
- Ovary13.16
- Kidney - Medulla7.6
- Uterus2.72
- Fallopian Tube1.8
- Cervix - Endocervix1.8
- Testis1.42
- Adrenal Gland0.66
- Bladder0.41
- Liver0.37
- Vagina0.35
- Minor Salivary Gland0.32
- Heart - Atrial Appendage0.3
- Prostate0.28
- Cervix - Ectocervix0.28
- Lung0.26
- Pituitary0.24
- Skin - Sun Exposed (Lower leg)0.23
- Esophagus - Mucosa0.2
- Spleen0.16
- Nerve - Tibial0.16
- Adipose - Visceral (Omentum)0.14
- Breast - Mammary Tissue0.13
- Skin - Not Sun Exposed (Suprapubic)0.13
- Brain - Substantia nigra0.12
And 29 more, listed on the interactive page.
- GO:0001822
- GO:0002003
- GO:0006508
- GO:0008217
- GO:0043408
- GO:0005576
- GO:0005886
- GO:0016020
- GO:0045177
- GO:0004190
- GO:0005102
- GO:0005515
- GO:0008233
Related records
Trials (165)
- "ALOFT - Aliskiren Observation of Heart Failure Treatment": Efficacy and Safety of Aliskiren Added on Top of Standard Therapy in Adults (≥ 18 Years) With Stable Heart Failure
- 52-104 Week Off-therapy Second Extension to Study CSPP100A2365
- 8 Weeks Study to Evaluate the Efficacy and Safety of Valsartan in Combination With Aliskiren Compared to Valsartan Alone in Patients With Stage 2 Hypertension
- 8-week Randomized, Open-label Study to Evaluate Food Effect on Efficacy and Safety of Oral Aliskiren 300 mg in Patients With Hypertension
- A Clinical Study to Assess Efficacy and Safety of Aliskiren in the Elderly With High Blood Pressure
- A Clinical Study to Compare an Aliskiren Based Hypertensive Regimen With a Ramipril Based One Followed by a Randomized Withdrawal.
- A Clinical Study to Compare Combination of Aliskiren+ HCTZ to Irbesartan+ HCTZ or Amlodipine+ HCTZ or HCTZ Alone in Obese Hypertensive Not Responsive to HCTZ 25 mg
- A Clinical Study to Compare Long-term Efficacy and Safety of an Aliskiren Based Regimen to a Hydrochlorothiazide Based Treatment Regimen With Optional Addition of Amlodipine
- A Clinical Study to Compare Long-term Efficacy and Safety of an Aliskiren Based Regimen to a Hydrochlorothiazidebased Treatment Regimen With Optional Addition of Amlodipine
- A Clinical Study to Compare the Safety and Efficacy of an Aliskiren-based Regimen With a Lisinopril Based Regimen in Patients With Severe Hypertension
- A Clinical Study to Evaluate Renal Hemodynamic Responses to Aliskiren in Patients With Type 2 Diabetes Mellitus
- A Clinical Study to Evaluate Safety & Efficacy of the Combination of Aliskiren, Valsartan & Hydrochlorothiazide in Diabetic Hypertensive Nonresponder Patients
- A Clinical Study to Evaluate the Long-term Safety (12 Months) of the Combination of Aliskiren 300 mg and Hydrochlorothiazide 25 mg
- A Clinical Study to Evaluate the Safety and Efficacy of Aliskiren Alone and in Combination With Ramipril in Hypertensive, Diabetic Patients.
- A Clinical Study to Evaluate the Safety and Efficacy of the Combination of Aliskiren and Amlodipine in Hypertensive Non Responders Patients
- A Clinical Study to Evaluate the Safety and Efficacy of the Combination of Aliskiren and Valsartan in Hypertensive Non Responders Patients
- A Clinical Study With Aliskiren Alone or in Combination Therapy With Diuretic Hctz in Venezuelan Hypertensive Patients.
- A Dose Ranging Study to Compare the Safety and Efficacy of Aliskiren 150mg, 300mg, and 600mg to Placebo in Patients With High Blood Pressure.
- A Dose Ranging Study to Compare the Safety and Efficacy of Aliskiren in Patients With High Blood Pressure
- A Long Term Safety Study to Test the Combination of Aliskiren/ Amlodipine / Hydrochlorothiazide in Participants With Essential Hypertension
Drugs (5)
- Aliskiren Renin inhibitor
- Aliskiren fumarate Renin inhibitor
- Imarikiren Renin inhibitor
- Imarikiren hydrochloride Renin inhibitor
- Sitokiren Renin inhibitor